Thromb Haemost 2006; 95(02): 390-392
DOI: 10.1055/s-0037-1612651
Case Report
Schattauer GmbH

Giant cell arteritis mimicking fever of unknown origin: potential diagnostic role of PET scan

Olivier Chavaillaz
1   Service of Ambulatory Investigation (OC, HS), Department of Community Medicine
,
Salah Gueddi
2   Division of Angiology and Hemostasis (SG, MR), Department of Internal Medicine
,
Sophia Taylor
3   Division of Pathology (ST), Department of Pathology and Immunology, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
,
Hans Stalder
1   Service of Ambulatory Investigation (OC, HS), Department of Community Medicine
,
Marc Righini
2   Division of Angiology and Hemostasis (SG, MR), Department of Internal Medicine
› Author Affiliations
Further Information

Publication History

Publication Date:
11 December 2017 (online)

 

 
  • References

  • 1 Hunder GG, Bloch DA, Michel BA. et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.
  • 2 Achkar AA, Lie JT, Hunder GG. et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?. Arch Intern Med 1994; 120: 987-92.
  • 3 Chmelewski WL, Mc Knight KM, Agudelo CA. et al. Presenting features and outcomes in patients undergoing temporal artery biopsy. Arch Intern Med 1992; 120: 1690-5.
  • 4 Ray-Chaudhuri N, Kine DA, Tijani SO. et al. Effects of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol 2002; 86: 530-2.
  • 5 Levine SM, Hellmann DB. Giant cell arteritis. Curr Opin Rheumatol 2002; 14: 3-10.
  • 6 Meller J, Strutz F, Siefker U. et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. EurJ Nucl Med Mol Imaging 2003; 30: 730-6.
  • 7 Klein RG, Hunder GG, Stanson AW. et al. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83: 806-12.
  • 8 Nordborg E, Nordborg C. Giant cell arteritis: strategies in diagnosis and treatment. Curr Opin Rheumatol 2004; 16: 25-30.
  • 9 Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30: 150-85.
  • 10 Zhuang H, Yu JQ, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 2005; 43: 121-34.
  • 11 Bleeker-Rovers CP, de Kleijn EM, Corstens FH. et al. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging 2004; 31: 29-37.
  • 12 Blockmans D, Knockaert D, Maes A. et al. Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001; 32: 191-6.
  • 13 Brodmann M, Passath A, Aigner R. et al. F18-FDGPET as a helpful tool in the diagnosis of giant cell arteritis. Rheumatology (Oxford) 2003; 42: 1264-6.
  • 14 Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol 2004; 17: 9-15.
  • 15 Brodmann M, Lipp RW, Passath A. et al. The role of 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. Rheumatology (Oxford) 2004; 43: 241-2.
  • 16 Karassa FB, Matsagas MI, Schmidt WA. et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 2005; 142: 359-69.
  • 17 Blockmans D, Stroobants S, Maes A. et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000; 108: 246-9.